Online citations, reference lists, and bibliographies.
← Back to Search

Integrated PET/CT: Current Applications And Future Directions.

G. V. von Schulthess, H. Steinert, T. Hany
Published 2006 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
For the past 5 years, combined positron emission tomography (PET) and computed tomography (CT), or PET/CT, has grown because the PET portion provides information that is very different from that obtainable with other imaging modalities. However, the paucity of anatomic landmarks on PET images makes a consistent "hardware fusion" to anatomic cross-sectional data extremely useful. Clinical experience indicates a single direction: Addition of CT to PET improves specificity foremost, but also sensitivity, and the addition of PET to CT adds sensitivity and specificity in tumor imaging. Thus, PET/CT is a more accurate test than either of its individual components and is probably also better than side-by-side viewing of images from both modalities. The synergistic advantage of adding CT is that the attenuation correction needed for PET can also be derived from the CT data, an advantage not obtainable by integrating PET and magnetic resonance imaging. This makes PET/CT 25%-30% faster than PET alone with standard attenuation-correction methods, leading to higher patient throughput and a more comfortable examination, which typically last 30 minutes or less. Fluorodeoxyglucose (FDG) PET/CT appears to provide relevant information in the staging and therapy monitoring of many tumors, including lung carcinoma, mesothelioma, colorectal cancer, lymphoma, melanoma, and many others, with the notable exception of prostatic cancer. For prostatic cancer, choline derivatives may become useful radiopharmaceuticals. The published literature on the applications of FDG PET/CT in oncology is still limited, but several well-designed studies have demonstrated the benefits of PET/CT.
This paper references
PET / CT and breast can
E Dizendorf
10.1016/S0360-3016(03)00346-8
Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study.
I. Ciernik (2003)
10.1148/RADIOLOGY.203.3.9169707
Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
F. Moog (1997)
10.1056/NEJM200104053441404
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
H. Joensuu (2001)
Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy.
T. Torizuka (1994)
10.1148/RADIOL.2352040494
Fluorocholine PET/CT in patients with prostate cancer: initial experience.
D. Schmid (2005)
10.1148/RADIOL.2292021598
Non-small cell lung cancer: dual-modality PET/CT in preoperative staging.
G. Antoch (2003)
rect comparison of ( 18 ) F - FDG PET and PET / CT in patients with colorectal carcinoma
C Cohade (1996)
Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma.
C. Cohade (2003)
Fluorodeoxyglucose positron emission tomography studies in the diagnosis and stag ing of clinically advanced prostate cancer
J Sung (2003)
Wholebody positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography
KD Stumpe (1998)
10.1148/RADIOL.2241011254
Recurrent laryngeal nerve palsy in patients with lung cancer: detection with PET-CT image fusion -- report of six cases.
E. M. Kamel (2002)
10.2214/AJR.182.6.1821579
PET-CT of extranodal lymphoma.
U. Metser (2004)
10.1148/RADIOLOGY.220.2.R01AU25373
Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors.
S. Hoegerle (2001)
Integrated PET/CT for the assessment of coronary artery disease: a feasibility study.
M. Namdar (2005)
10.1148/RADIOL.2312021596
FDG PET for differentiation of infection and aseptic loosening in total hip replacements: comparison with conventional radiography and three-phase bone scintigraphy.
K. Stumpe (2004)
10.1016/S0969-8051(03)00097-0
Synthesis and evaluation of O-(3-[18F]fluoropropyl)-L-tyrosine as an oncologic PET tracer.
Ganghua Tang (2003)
10.1016/0969-8051(96)00080-7
Cost-effectiveness of PET imaging in clinical oncology.
P. Valk (1996)
10.1200/JCO.2001.19.17.3745
Lymph node staging by positron emission tomography in patients with carcinoma of the cervix.
P. Grigsby (2001)
Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging—do we need contrastenhanced CT? Radiology
NG Schaefer (2004)
10.1111/j.1464-410X.2003.04692.x
Diagnosis of local recurrence after radical prostatectomy
V. Scattoni (2004)
10.1148/RADIOL.2311030271
Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion.
H. Schöder (2004)
10.1007/s00259-004-1633-7
The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate
G. Goerres (2004)
10.1067/MSY.2001.116919
Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup.
E. Zervos (2001)
10.1097/00000658-198908000-00001
Resection of hepatic metastases from colorectal cancer. Biologic perspective.
G. Steele (1989)
10.1016/J.IJROBP.2003.10.044
Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
J. Bradley (2004)
10.1118/1.598392
Attenuation correction for a combined 3D PET/CT scanner.
P. Kinahan (1998)
10.1007/s00259-003-1338-3
Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation
C. Bleeker-Rovers (2003)
PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
Z. Keidar (2004)
10.1002/1097-0142(19920601)69:11<2796::AID-CNCR2820691127>3.0.CO;2-O
Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone
C. Perez (1992)
10.1046/j.1464-410X.2003.04297.x
Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer
J. Sung (2003)
Teflon-induced granuloma: a false-positive finding with PET resolved with combined PET and CT.
Rita A Yeretsian (2003)
USA-Fat"): description on 18F-FDG PET/CT
C Cohade (2003)
Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies.
E. Dizendorf (2003)
10.1046/j.1365-2141.2003.04617.x
18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non‐Hodgkin's lymphoma
J. Zijlstra (2003)
10.1007/s00261-003-0163-2
Incremental value of CT in PET/CT of patients with colorectal carcinoma
I. Kamel (2003)
10.2106/00004623-200105000-00002
Fluorine-18 Fluorodeoxyglucose-Positron Emission Tomography: A Highly Accurate Imaging Modality for the Diagnosis of Chronic Musculoskeletal Infections
F. De Winter (2001)
10.1023/A:1008486928190
Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.
M. Bangerter (1998)
Uptake in supraclavicular area fat ("USA-Fat"): description on 18F-FDG PET/CT.
C. Cohade (2003)
Clinical molecular anatomic imaging : PET, PET/CT, and SPECT/CT
G. Schulthess (2003)
Direct Comparison of 18F-FDG PET and PET/CT in Patients with Colorectal Carcinoma
C. Cohade (2003)
10.1007/s002590050275
Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography
K. Stumpe (1998)
In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET.
T. Torizuka (1995)
10.3816/CLM.2002.N.012
Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL.
G. Jerusalem (2002)
Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Y. Kitagawa (2003)
10.1007/s00259-002-0796-3
PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients
C. Burger (2002)
10.1007/s00330-002-1564-2
Impact of metallic dental implants on CT-based attenuation correction in a combined PET/CT scanner
Ehab M. Kamel (2002)
10.1007/s00259-002-1055-3
PET-CT: accuracy of PET and CT spatial registration of lung lesions
C. Cohade (2003)
Cancer,Facts and Figures about.
U. G. Dailey
10.1002/cncr.10336
Comparison of fluorine‐18 fluorodeoxyglucose positron emission tomography and Ga‐67 scintigraphy in evaluation of lymphoma
L. Kostakoglu (2002)
10.1002/CNCR.2820710205
Ovarian cancer: Age contrasts in incidence, histology, disease stage at diagnosis, and mortality
R. Yancik (1993)
10.1148/RADIOLOGY.206.3.9494497
Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.
H. Abdel-Nabi (1998)
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.
G. Antoch (2004)
10.1007/s00261-003-0118-7
PET-CT detection of abdominal recurrence of ovarian cancer: radiologic–surgical correlation
H. Pannu (2003)
Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results.
E. M. Kamel (2004)
Correction for oral contrast artifacts in CT attenuation-corrected PET images obtained by combined PET/CT.
S. Nehmeh (2003)
10.1148/RADIOL.2332031800
Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings.
S. Sironi (2004)
[The impact of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) on planning of radiotherapy].
E. Dizendorf (2001)
10.1148/RADIOL.2262011939
Detection of metallic implant-associated infections with FDG PET in patients with trauma: correlation with microbiologic results.
M. Schiesser (2003)
10.1016/S0003-4975(00)01817-8
Where is the boundary between N1 and N2 stations in lung cancer?
H. Asamura (2000)
10.1007/s00259-002-1070-4
CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET
D. Visvikis (2002)
Ovarian
R Yancik
Malignant pleural mesothelioma: response evaluation with integrated PET-CT imaging (abstr)
MM Santos Dellea (2004)
Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its costeffectiveness
S Heinrich (2005)
A combined PET/CT scanner for clinical oncology.
T. Beyer (2000)
10.1056/NEJMOA022136
Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.
D. Lardinois (2003)
10.1016/S1536-1632(03)00035-0
PET/CT using 2-deoxy-2-[18F]fluoro-D-glucose for the evaluation of suspected infected vascular graft.
Z. Keidar (2003)
10.7326/0003-4819-129-1-199807010-00007
Surgery for Recurrent Colon Cancer: Strategies for Identifying Resectable Recurrence and Success Rates after Resection
R. Goldberg (1998)
10.1148/RADIOL.2323031065
Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection.
E. Even-Sapir (2004)
10.1016/S0360-3016(03)01625-0
Can post-RT neck dissection be omitted for patients with head-and-neck cancer who have a negative PET scan after definitive radiation therapy?
J. W. Rogers (2004)
The impact of 18Ffluorodeoxyglucose positron emission tomography (FDG-PET) on planning of radiotherapy [in Russian
E Dizendorf (2001)
Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making.
Iva Kantorová (2003)
10.1097/01.sla.0000172095.97787.84
Positron Emission Tomography/Computed Tomography Influences on the Management of Resectable Pancreatic Cancer and Its Cost-Effectiveness
Stefan Heinrich (2005)
10.1148/RADIOL.2323030985
Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
N. Schaefer (2004)
10.1097/01.sla.0000146145.69835.c5
Does the Novel PET/CT Imaging Modality Impact on the Treatment of Patients With Metastatic Colorectal Cancer of the Liver?
M. Selzner (2004)
10.1148/RADIOL.2263011732
Respiration-induced attenuation artifact at PET/CT: technical considerations.
G. Goerres (2003)
10.1007/s00259-001-0698-9
CT vs 68Ge attenuation correction in a combined PET/CT system: evaluation of the effect of lowering the CT tube current
E. Kamel (2001)
10.1016/0090-8258(90)90085-Y
Clinical-pathologic study of stage IIB, III, and IVA carcinoma of the cervix: extended diagnostic evaluation for paraaortic node metastasis--a Gynecologic Oncology Group study.
P. Heller (1990)
10.1097/00000658-200103000-00003
Decision Analysis for the Cost-Effective Management of Recurrent Colorectal Cancer
K. Park (2001)
10.1200/JCO.1999.17.3.894
Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer.
P. Flamen (1999)
Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT.
H. Lerman (2004)
10.1007/s00259-004-1536-7
PET/CT and breast cancer
B. Zangheri (2004)
Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004;231(1):65–72
H Schoder (2004)
Routine 18F-FDG PET Preoperative Staging of Colorectal Cancer: Comparison with Conventional Staging and Its Impact on Treatment Decision Making
Iva Kantorová (2003)
10.1200/JCO.2004.08.120
Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.
G. Antoch (2004)
10.1007/s00259-004-1593-y
Side-by-side reading of PET and CT scans in oncology: which patients might profit from integrated PET/CT?
P. Reinartz (2004)
10.1016/J.YGYNO.2004.05.053
The diagnostic accuracy of 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies.
D. Grisaru (2004)
Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment.
M. Picchio (2003)
10.1007/s00259-003-1408-6
FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT
K. Kubota (2003)
10.1200/JCO.20.2.388
Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
T. Ruers (2002)
10.1016/J.RCL.2004.07.006
Investigation of thyroid, head, and neck cancers with PET.
H. Zhuang (2004)
10.1148/RADIOL.2252011568
PET diagnostic accuracy: improvement with in-line PET-CT system: initial results.
T. Hany (2002)
10.1093/ANNONC/MDF664
The value of positron emission tomography (PET) imaging in disease staging and therapy assessment.
G. Jerusalem (2002)
pact of FDG - PET on radiation therapy volume delineation in non - small - cell lung can
M Namdar (2004)
A tabulated summary of the FDG PET literature.
M. Spieth (2002)



This paper is referenced by
10.1007/S12149-007-0010-6
2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience
T. Komori (2007)
10.1016/B978-0-444-53086-8.00004-7
Chapter 4 – [18F]‐Labeled PET and PET/CT Compounds in Oncology
K. Herrmann (2008)
10.1088/0031-9155/54/1/R01
Biological imaging in radiation therapy: role of positron emission tomography.
U. Nestle (2009)
10.1007/174_2010_5
PET/CT in Pancreatic Cancer
Thomas F. Hany (2010)
10.3310/hta15180
An economic evaluation of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
P. Auguste (2011)
10.1007/s00330-010-1862-z
PET/CT in primary musculoskeletal tumours: a step forward
A. Lakkaraju (2010)
Clinical significance of small pulmonary nodules with little or no 18F-FDG uptake on PET/CT images of patients with nonthoracic malignancies.
J. O (2007)
Tumour Grading and Discrimination based on Class Assignment and Quantitative Texture Analysis Techni
Omar Sultan Al-Kadi (2009)
A prospective clinical trial of tumor hypoxia imaging with 18 F-fluoromisonidazole positron emission tomography and computed tomography ( F-MISO PET / CT ) before and during radiation therapy
Izumi Tachibana (2013)
10.6332/ANMS.2303.002
Impact of CT-based Attenuation Correction in Thallium-201 Myocardial Perfusion Imaging
Jih-Fang Hsieh (2010)
10.1118/1.3310381
Evaluation of the spatial dependence of the point spread function in 2D PET image reconstruction using LOR-OSEM.
D. Wiant (2010)
10.1016/j.ejrad.2010.08.016
Diffusion weighted imaging: lymph nodes.
A. Herneth (2010)
10.3748/wjg.v21.i26.7988
Current status and progress of pancreatic cancer in China.
Quan-Jun Lin (2015)
10.1007/s11307-009-0266-4
Acquisition Parameters for Oncologic Imaging with a New SPECT/Multislice CT Scanner
R. Núñez (2009)
10.1053/j.semnuclmed.2015.03.002
PET/MRI in the Upper Abdomen.
M. Gavra (2015)
10.1148/rg.324115143
State-of-the-art PET/CT of the pancreas: current role and emerging indications.
D. Sahani (2012)
10.1016/j.crad.2007.11.008
The role of hybrid SPECT-CT in oncology: current and emerging clinical applications.
F. Chowdhury (2008)
10.1007/978-3-540-85689-4_28
Whole-Body MRI
Philip Aschoff (2009)
10.1148/radiol.2532081445
Value of 18F-fluoro-L-dopa PET in the preoperative localization of focal lesions in congenital hyperinsulinism.
C. Capito (2009)
Simulation and image reconstruction of clinical TOF-PET scanners
K. M. Abushab (2013)
Adaptive modelling of tumour volume dynamics under radiotherapy
Imran Tariq (2016)
10.1097/RLU.0b013e31818f4588
Ga-68 DOTATOC PET/CT changed the therapeutic course of a patient with the sudden onset of vision problems.
J. Van Riet (2009)
10.1159/000354842
Limited Positron Emission Tomography-Computed Tomography for Restaging of Lymphoma: A Strategy for Reducing Radiation Exposure among Patients with Early-Stage Curable Lymphoma
O. Wolach (2013)
F-FDG PET / CT can be used to detect non-functioning pancreatic neuroendocrine tumors
G. Luo (2014)
Současné možnosti pozitronové emisní tomografie a integrované pozitronové emisní tomografie s počítačovou tomografií v iniciálním stážování a hodnocení léčebné odpovědi u ne-hodgkinových lymfomů
Tomáš Papajík CSc (2009)
10.6332/ANMS.2301.001
The Utility of PET and CT in the Differential Diagnosis of Pancreatic Masses: A Prospective Study in 34 Patients
J. Chen (2010)
10.1016/J.MEDNUC.2010.07.019
TEP/TDM dans le diagnostic et la stadification des lymphomes
X. Setoain (2011)
10.1016/J.EJRNM.2016.03.002
Do we need 18F-FDG PET/CT scan in staging and management of testicular tumors?
T. W. Kassem (2016)
10.1007/s12032-010-9675-0
Lymphoma of the breast in a male patient
B. Duman (2011)
Sources and resources for oncologists to help answer the question: is PET/CT appropriate for my patient?
D. Karantanis (2012)
Meme kanserinde sentinel lenf nodülü saptanmasinda planar lenfosintigrafi ve SPECT/BT Planar lymphoscintigraphy and SPECT/CT in detection of sentinel lymph node in breast cancer
P. Arıcan (2012)
10.1007/s10147-006-0595-0
PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients
K. Endo (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar